Fly News Breaks for March 9, 2015
CTIC
Mar 9, 2015 | 11:12 EDT
Piper said CTI BioPharma's details from the PERSIST-1 readout on efficacy and safety profile are consistent or better than expected based on the II data. As a result, the firm raised CTI's price target to $8 and reiterates its Overweight rating.
News For CTIC From the Last 2 Days
There are no results for your query CTIC